Clinical and experimental obstetrics & gynecology · 2011
Chronic pelvic pain--traditional and novel therapies: part II medical therapy.
Редакционная статьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Check J H, Cohen R
Аннотация
PURPOSE: To describe medical therapeutic options for chronic pelvic pain. Furthermore to describe some new concepts in the etiology of chronic pelvic pain leading to some novel therapies.
METHODS: The benefits and risks of various medical treatments for chronic pelvic pain including central pain, cyclic pain, vulvar pain and bladder pain are discussed.
RESULTS: Among various conventional therapies the medical therapy with the most benefit with the least risks are low-dose impeded androgens, oral contraceptives, or low dosage progesterone/progestins.
CONCLUSIONS: The various types of pelvic pain may all be different manifestations of a common etiology related to defects in the sympathetic nervous system. Sympathomimetic amine therapy may be the most effective therapy with the least side-effects. However, at the moment this schedule II drug has not been approved for this use and thus must be used off-label.
METHODS: The benefits and risks of various medical treatments for chronic pelvic pain including central pain, cyclic pain, vulvar pain and bladder pain are discussed.
RESULTS: Among various conventional therapies the medical therapy with the most benefit with the least risks are low-dose impeded androgens, oral contraceptives, or low dosage progesterone/progestins.
CONCLUSIONS: The various types of pelvic pain may all be different manifestations of a common etiology related to defects in the sympathetic nervous system. Sympathomimetic amine therapy may be the most effective therapy with the least side-effects. However, at the moment this schedule II drug has not been approved for this use and thus must be used off-label.